Text Size
109 studies found for:    KLH

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Completed Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route
Condition: Atopic Dermatitis
Intervention: Biological: KLH carrier-protein
2 Active, not recruiting A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)
Condition: Autoimmune Disorders
Interventions: Biological: Subcutaneous Immucothel;   Biological: subcutaneous Immucothel plus Montanide;   Biological: Oral KLH followed by immunization
3 Terminated Vaccination With Tetanus and KLH to Assess Immune Responses.
Condition: Cancer
Interventions: Biological: Intracel KLH Vaccine;   Biological: Biosyn KLH;   Drug: Montanide ISA51;   Biological: Tetanus toxoid
4 Completed Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21
Condition: Prostate Cancer
Intervention: Biological: MUC-2-KLH
5 Active, not recruiting Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab
Conditions: Fallopian Tubes Cancer;   Ovarian Cancer;   Peritoneal Cancer
Intervention: Biological: bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821
6 Recruiting Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid
Condition: Lung Cancer
Interventions: Biological: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant;   Biological: Biological/Vaccine: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant
7 Active, not recruiting A Randomized, Placebo-controlled, Double-blind Study of KLH-2109 in Patients With Endometriosis (2)
Condition: Endometriosis
Interventions: Drug: KLH-2109;   Drug: placebo
8 Completed Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With Immunological Adjuvant QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV Cutaneous Melanoma
Condition: Melanoma
Intervention: Biological: KLH conjugates with GD2L and GD3L
9 Active, not recruiting A Randomized Open Label Study of KLH-2109 in Patients With Endometriosis(1)
Condition: Endometriosis
Intervention: Drug: KLH-2109
10 Active, not recruiting A Phase II Randomized Open Label Study of KLH-2109 in Patients With Endometriosis
Condition: Endometriosis
Intervention: Drug: KLH-2109
11 Unknown † Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma
Conditions: Brain and Central Nervous System Tumors;   Lymphoma;   Lymphoproliferative Disorder;   Small Intestine Cancer
Interventions: Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine;   Biological: sargramostim;   Drug: methotrexate;   Drug: thiotepa;   Radiation: radiation therapy
12 Active, not recruiting Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine;   Biological: sargramostim;   Biological: aldesleukin;   Other: laboratory biomarker analysis
13 Recruiting Id-KLH Vaccine + T Cells
Condition: Multiple Myeloma
Intervention: Biological: CD3/CD28
14 Completed Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: QS21;   Biological: TF(c)-KLH conjugate vaccine;   Biological: Thomsen-Friedenreich antigen;   Biological: keyhole limpet hemocyanin
15 Completed Keyhole Limpet Hemocyanin in Chronic Hepatitis C
Conditions: Chronic Hepatitis C;   Liver Cirrhosis
Intervention: Drug: keyhole-limpet hemocyanin
16 Active, not recruiting Direct Tumor Injection KLH-Pulsed Dendritic Cells in Unresectable Pancreatic Cancer
Condition: Metastatic Pancreatic Cancer
Intervention: Biological: KLH-pulsed autologous dendritic cell vaccine
17 Active, not recruiting Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery
Condition: Malignant Neoplasms of Brain
Interventions: Biological: PEP-3-KLH conjugate vaccine;   Biological: daclizumab;   Drug: temozolomide;   Other: placebo;   Biological: PEP-3-KLH
18 Unknown † Rituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Biological: Id-KLH
19 Recruiting Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral ß-glucan for High-Risk Neuroblastoma
Condition: Neuroblastoma
Intervention: Biological: adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH
20 Completed Idiotype Vaccine Following High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Patients With Lymphoma Who Had Failed Induction Chemotherapy
Condition: Lymphoma
Intervention: Biological: Id-KLH
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years